Beyond the hype: Key components of an effective AI policy; CIO, October 2, 2024

  Leo Rajapakse, CIO; Beyond the hype: Key components of an effective AI policy

"An AI policy is a living document 

Crafting an AI policy for your company is increasingly important due to the rapid growth and impact of AI technologies. By prioritizing ethical considerations, data governance, transparency and compliance, companies can harness the transformative potential of AI while mitigating risks and building trust with stakeholders. Remember, an effective AI policy is a living document that evolves with technological advancements and societal expectations. By investing in responsible AI practices today, businesses can pave the way for a sustainable and ethical future tomorrow."

The government dropped its case against Gang Chen. Scientists still see damage done; WBUR, February 16, 2022

Max Larkin, WBUR ; The government dropped its case against Gang Chen. Scientists still see damage done

"When federal prosecutors dropped all charges against MIT professor Gang Chen in late January, many researchers rejoiced in Greater Boston and beyond.

Chen had spent the previous year fighting charges that he had lied and omitted information on U.S. federal grant applications. His vindication was a setback for the "China Initiative," a controversial Trump-era legal campaign aimed at cracking down on the theft of American research and intellectual property by the Chinese government.

Researchers working in the United States say the China Initiative has harmed both their fellow scientists and science itself — as a global cooperative endeavor. But as U.S.-China tensions remain high, the initiative remains in place."

A Little-Known Statute Compels Medical Research Transparency. Compliance Is Pretty Shabby.; On The Media, April 21, 2021

 On The Media; A Little-Known Statute Compels Medical Research Transparency. Compliance Is Pretty Shabby.

"Evidence-based medicine requires just that: evidence. Access to the collective pool of knowledge produced by clinical trials is what allows researchers to safely and effectively design future studies. It's what allows doctors to make the most informed decisions for their patients.

Since 2007, researchers have been required by law to publish the findings of any clinical trial with human subjects within a year of the trial's conclusion. Over a decade later, even the country's most well-renown research institutions sport poor reporting records. This week, Bob spoke with Charles Piller, an investigative journalist at Science Magazine who's been documenting this dismal state of affairs since 2015. He recently published an op-ed in the New York Times urging President Biden to make good on his 2016 "promise" to start withholding funds to force compliance."